3 Under-the-Radar Biotech Stocks to Buy in 2023
Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer.
Deciphera Pharmaceuticals (NASDAQ: DCPH), Mirati Therapeutics (NASDAQ: MRTX) and MacroGenics (NASDAQ: MGNX) are lesser-known biotech companies with significant potential since they focus on oncology therapies. However, the stock prices of all three have fallen this year, meaning their shares can still be bought at a decent price point.
All three have seen a boost in second-quarter finances and have late-stage therapies with promise in their pipelines.
Source Fool.com
Mirati Therapeutics Inc. Stock
€53.84
-0.040%
The sentiment is rather negative at the moment with 10 Sell predictions and 2 Buy predictions.
On the other hand, the target price of 78 € is above the current price of 53.84 € for Mirati Therapeutics Inc., so the potential is actually 44.87%.
